Patents by Inventor Sandra Morel

Sandra Morel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of adjuvants for the prevention and/or treatment of autoimmune diseases
    Patent number: 11311618
    Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 26, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, GLAXOSMITHKLINE BIOLOGICALS SA, SORBONNE UNIVERSITE
    Inventors: Sandra Morel, Charlotte Véronique Pouchy, Benoit Laurent Salomon, Nathalie Raoul Liliane Vanerheyde
  • USE OF ADJUVANTS FOR THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20200261569
    Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 20, 2020
    Applicants: GLAXOSMITHKLINE BIOLOGICALS, SA, SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Sandra MOREL, Charlotte Véronique POUCHY, Benoit Laurent SALOMON, Nathalie Raoul Liliane VANERHEYDE
  • Recombinant adenylate cyclase toxin of induces T cell responses against tumoral antigens
    Patent number: 9410139
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 9, 2016
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), LUDWIG INSTITUT FOR CANCER RESEARCH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoît Van Den Eynde, Sandra Morel, Cécile Bauche
  • RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS
    Publication number: 20140227323
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: October 25, 2013
    Publication date: August 14, 2014
    Applicants: Ludwig Institute for Cancer, Institut Pasteur
    Inventors: Gilles DADAGLIO, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecil Bauche
  • RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS
    Publication number: 20100310594
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: March 25, 2010
    Publication date: December 9, 2010
    Applicants: Institut Pasteur, a corporation of France, Ludwig Institute for Cancer, a corporation of New York
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
  • Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
    Publication number: 20090117143
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: September 12, 2008
    Publication date: May 7, 2009
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
  • Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
    Publication number: 20070026022
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: May 19, 2006
    Publication date: February 1, 2007
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Eynde, Sandra Morel, Cecile Bauche
  • Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
    Publication number: 20050271679
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: November 22, 2004
    Publication date: December 8, 2005
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
  • Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
    Patent number: 6667037
    Abstract: The invention relates to peptides which bind to HLA-B35 molecules, leading to recognition and lysis of the resulting complexes by cytolytic T cells. Also a part of the invention are nucleic acid molecules which encode these peptides, and uses of each of these. The molecules are derived, in some cases, from tyrosinase, and portions of the tyrosinase molecule and portions of nucleic acid molecules which encode tyrosinase are also a part of the invention.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: December 23, 2003
    Assignees: Ludwig Institute for Cancer Research, Universite de Liege
    Inventors: Annie Ooms, Gérard De Giiovanni, Sandra Morel, Benoît Van Den Eynde, Thierry Boon-Falleur